Identifying cancer treatment targets using genetic analysis in mice
Official title: Defining Cancer Intervention Targets by Functional Genomics Analysis of Outbred F1 Mice
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-11011468 · Data updated 2026-11-12
This study is looking at how certain genes can help slow down breast cancer growth and stop it from coming back, using mice to find out more about a molecule called LILRB4 that affects how the immune system fights tumors, with the hope of discovering new ways to improve treatment for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | March 1, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $576,403 |
| NIH project number | 5R01CA278818-03 |
| Project ID | NIH-11011468 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with breast or lung cancer, particularly those with HER2/neu expression.
✕Less likely to help
Patients with cancers unrelated to HER2/neu or those who do not express the targeted regulatory genes may not benefit from this research.
What this research studies
This research investigates how targeting specific regulatory genes can slow down tumor growth and prevent cancer from returning. By studying genetically diverse mice that develop breast tumors, researchers aim to identify key genes involved in cancer progression and test new treatment strategies. The study focuses on a molecule called LILRB4, which plays a role in how the immune system interacts with tumors. Through advanced genetic analysis and bioinformatics, the research seeks to uncover actionable targets that could improve cancer treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that enhance anti-tumor immunity and improve survival rates for cancer patients.
How similar studies have gone: Previous research has shown promise in targeting similar regulatory genes for cancer treatment, indicating a potential for success in this approach.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Jacob, Jennifer B — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Jacob, Jennifer B
Related research
Other NIH-funded projects on the same topics.
-
Keloid recurrence study using multi-omics in diverse patients
A research effort will look at why keloids come back after surgery, especially in African American patients, using comprehensive molecular data from patient samples.
-
A national program to build a precise, personalized health data platform for all of us participants
This grant supports expanding and improving a national health data platform to help tailor care to each person using their genetic, health, and lifestyle information.
-
Computational modeling of female hormone balance and drug responses
A new computational model uses patient-like data to predict how metabolic drugs will work in women across their hormonal cycles and different reproductive stages.
-
Anti-CD38 immunotherapy for severe hidradenitis suppurativa
A new treatment using anti-CD38 therapy is being tested for people with severe hidradenitis suppurativa who have not responded to prior therapies.
-
Vitamin D, gut bacteria and dementia risk in older adults with HIV
This work will look at whether low vitamin D and changes in gut bacteria are linked to higher dementia risk in older adults living with chronic HIV and similar community members.
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.